Skip to main content

15-11-2017 | Rheumatology | News | Article

News in brief

Extended benefits of ixekizumab treatment in patients with PsA

medwireNews: Results from the extension phase of the SPIRIT-P2 trial suggest that the benefits of treatment with ixekizumab are maintained for up to 1 year among patients with psoriatic arthritis (PsA).

The primary trial results – presented previously at the EULAR 2017 congress – demonstrated efficacy of the interleukin (IL)-17A inhibitor relative to placebo among PsA patients with an inadequate response to anti-tumor necrosis factor (TNF) treatment, the presenting author told delegates at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA.

The proportion of patients who achieved at least a 20% improvement in ACR criteria (ACR20) increased from 53% at week 24 to 84% at week 52 among the 119 patients who were randomly assigned to receive ixekizumab 80 mg every 4 weeks, and from 48% to 75% among the 123 patients who received the drug every 2 weeks.

There was also a “consistency of response” in skin scores and in the resolution of enthesitis and dactylitis at week 52, with “slight trends in favor of the every 4 week regimen,” said Mark Genovese (Stanford University School of Medicine, Palo Alto, California, USA).

He noted that the safety profile of ixekizumab observed in the extension period to date is consistent with what was seen during the 24-week trial, and “continues to be consistent with what is known about [ixekizumab] to date.”

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology

See the research in context now

with trial summaries, expert opinion and congress coverage